Amphotericin B is a valuable drug for the treatment of systemic fungal infections. In the conventional intravenous preparation, it is presented as a deoxycholate complex and in this form frequently causes serious unwanted effects, particularly renal damage. Recently a novel formulation of amphotericin B has been introduced in which the drug is delivered in liposomes (AmBisome – Vestar). The manufacturer claims that AmBisome is less toxic, and can be used in higher doses than the conventional preparation. Does AmBisome have any real clinical advantage?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.